Cargando…
Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro
Glioblastoma is a disease characterized by rapid invasive tumour growth. Studies on the proapoptotic CD95/CD95L signalling pathway recently suggested a significant contribution of CD95 signalling towards the high degree of motility in glioma cells. Apogenix has developed APG101, a clinical phase II...
Autores principales: | Merz, Christian, Strecker, Alexander, Sykora, Jaromir, Hill, Oliver, Fricke, Harald, Angel, Peter, Gieffers, Christian, Peterziel, Heike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484665/ https://www.ncbi.nlm.nih.gov/pubmed/25850884 http://dx.doi.org/10.1097/CAD.0000000000000237 |
Ejemplares similares
-
The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells
por: Legler, Karen, et al.
Publicado: (2018) -
APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis
por: Raimbault, Anna, et al.
Publicado: (2016) -
CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence
por: Richards, David M, et al.
Publicado: (2021) -
A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity
por: Thiemann, Meinolf, et al.
Publicado: (2018) -
HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality
por: Richards, David M., et al.
Publicado: (2019)